enGene Therapeutics Inc. (ENGN)
| Market Cap | 113.88M -39.4% |
| Revenue (ttm) | n/a |
| Net Income | -126.85M |
| EPS | -2.12 |
| Shares Out | 66.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,670,435 |
| Open | 1.820 |
| Previous Close | 1.820 |
| Day's Range | 1.690 - 1.830 |
| 52-Week Range | 1.400 - 12.250 |
| Beta | -0.28 |
| Analysts | Hold |
| Price Target | 3.29 (+93.53%) |
| Earnings Date | Sep 10, 2026 |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ENGN stock is "Hold." The 12-month stock price target is $3.29, which is an increase of 93.53% from the latest price.
News
enGene Therapeutics Transcript: KOL event
The event highlighted the expanding NMIBC market, driven by new therapies and increased sequencing, with detalimogene positioned as a differentiated, non-viral gene therapy offering strong efficacy, safety, and ease of use. Market research and KOL insights support its broad adoption and significant commercial potential.
enGene Therapeutics Slides: KOL event
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtu...
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of D...
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to ...
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for ...
enGene Therapeutics Earnings release: Q2 2026
enGene Therapeutics released its Q2 2026 earnings on June 15, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q2 2026
enGene Therapeutics has published its Q2 2026 quarterly earnings report on June 15, 2026.
enGene Therapeutics Transcript: AGM 2026
The meeting confirmed quorum, reviewed and approved the election of four directors until 2029, and reappointed KPMG LLP as auditor. All proposals passed with strong shareholder support, and no questions were raised on the main items.
enGene Therapeutics Proxy statement: Proxy filing
enGene Therapeutics filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGen...
enGene Therapeutics Transcript: Study result
LEGEND pivotal cohort data show detalimogene achieves a 54% CR at any time and 43% at six months, with strong tolerability and low discontinuation rates. Lower CR rates in the latest subgroup are under review, and a new surfactant cohort aims to boost efficacy. BLA filing is planned after full data maturation.
enGene Therapeutics Slides: Study result
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
enGene Therapeutics Press release: Study result
enGene Therapeutics issued a press release on May 7, 2026, disclosing material business information to investors.
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim resul...
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleas...
enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026
NMIBC treatment is shifting from radical surgery to more tolerable, effective therapies, with detalimogene showing strong efficacy and ease of use for community urologists. Key data updates are expected in Q2 and later this year, supporting a potential 2027 approval.
enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Detalimogene, a non-viral gene therapy for NMIBC, is advancing through pivotal trials with strong regulatory support and a focus on community urologists. The product's ease of use, competitive efficacy, and favorable tolerability are expected to drive adoption as the market shifts toward sequencing therapies.
enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Major protocol amendments and improved execution have driven higher response rates in the pivotal cohort, with 12-month data expected later this year. Regulatory engagement is strong, aided by RMAT and CDRP designations, and the product is positioned for broad adoption in community urology practices due to its ease of use and favorable economics.
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...
enGene Therapeutics Earnings release: Q1 2026
enGene Therapeutics released its Q1 2026 earnings on March 9, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q1 2026
enGene Therapeutics has published its Q1 2026 quarterly earnings report on March 9, 2026.
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.